01.21.26 -- 7 Outsourcing Behaviors For 2026 That Will Protect Timelines

Join Outsourced Pharma Chief Editor Jeff Buguliskis and our panel of industry experts as they share practical advice, reveal what to look for beyond the surface, and answer your toughest questions about selecting a CDMO partner that can truly deliver. Register for free today!

We are beginning to see a rise in the interest of developing "orphan drugs," or pharmaceutical agents. Discover challenges associated with the development and how to successfully work through them.

To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.

CDMO selection requires evaluating experience, quality standards, and flexibility. Assess technical transfer skills, supply chain security, and collaborative approach for a reliable, long-term project fit.

Fixing limited capacity in pharmaceutical CMC development starts with understanding a complex web of root causes.

Learn how a scientific framework for early-phase CMC development, integrating QbD and proactive risk management, helps de-risk drug development and accelerate the journey from molecule to market.

Bridging the gap between startup and long-term sustainability requires a unified strategy. Transform early readiness metrics into a durable operating system that drives performance improvements.

Review how the EMA supports rare disease drug development through regulatory and financial incentives for therapies that meet strict eligibility and ongoing compliance criteria.

How do biopharma companies solve the common challenge of increasing output while decreasing headcount? Explore three options: temporary staffing, outsourcing, and insourcing.

We are a global CDMO with a network of cGMP facilities in key markets. From early development to commercial scale, we handle the manufacturing and testing that help your therapies advance.

Highly potent APIs require stringent containment and precise manufacturing controls. Specialized facilities offer end-to-end development solutions and robust cross-contamination protections.

Our injectable and solid dosage form products are manufactured at state-of-the-art facilities located in the Madrid metropolitan area of Spain.